Alector Inc (ALEC)
Alector, Inc. is a clinical-stage biotechnology company focused on developing therapies designed to address the progression of neurodegenerative diseases in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody, along with other programs in preclinical development such as AL137 for Alzheimer’s disease, AL050 for Parkinson’s disease and Lewy body dementia in patients with GBA1 gene mutations, AL064 for Alzheimer’s disease and other tau-related disorders, ADP062-ABC for Parkinson’s disease, and ADP065-ABC for neurodegenerative conditions. The company also has a strategic collaboration with GlaxoSmithKline plc covering progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. Founded in 2013, Alector is headquartered in South San Francisco, California, and its common stock is listed on NASDAQ under the ticker ALEC.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ALEC
|
$1.91
|
-5.1% Downside
|
Fair
|
$3.10
|
54.2% Upside
|
Bargain
|
Weak
|
0.0%
|
November 10, 2026
|
16.2x
|
224.4 M
|
84.39 M
|
13.1%
|
80.1%
|
-7.5
|
134.4%
|
